NewsRoom Articles - Page 17 of 174

WednesdayOct 25, 2023 12:13 pm

Four Marketing Channels that eCommerce Firms Can Leverage

In an incredibly competitive market such as e-commerce, where 90% of companies fail, marketing is key to standing out from the competition and maintaining profitability. The right marketing channel mix can help you drive traffic to your merchant sites, increase conversions and boost your virtual store’s revenue. Although billions of people buy and sell online every year, attracting and retaining customers to a platform can be incredibly difficult. Traditional marketing techniques may not translate well to e-commerce. Even with the right techniques, you may not have much marketing success if you don’t devise a proper mix of marketing channels. Search…

WednesdayOct 25, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS

Clene's wholly-owned subsidiary, Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”) The study will monitor safety, survival, clinical worsening, and key disease progression-related biomarkers while using CNM-Au8 Research conducted by Clene estimates that ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the US and an estimated 500,000 people worldwide, with a life expectancy of diagnosed patients typically ranging from three to five years Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on…

TuesdayOct 24, 2023 9:37 am

Spanish Clinical Trial to Explore Marijuana as Glioblastoma Treatment

A major marijuana company has announced that it will begin supplying cannabis to a Spanish clinical trial investigating marijuana’s potential as a glioblastoma treatment. Tilray Brands subsidiary Tilray Medical will sponsor an upcoming clinical study to test whether marijuana can treat glioblastoma, one of the hardest-to-treat types of brain cancer. The study will be conducted by Complutense University of Madrid and Spanish Neuro-Oncology Research Group (GEINO) scientists at Madrid’s University Hospital. For the research, researchers will recruit 30 recently diagnosed glioblastoma patients from eight neurooncology specialized sites in Spain, they will use T10:C10, a THC and CBD extract from Tilray…

MondayOct 23, 2023 12:46 pm

Five Ways to Treat Infectious Diseases While Keeping Antimicrobial Resistance in Check

Proper and early treatment is crucial to preventing worse patient outcomes and limiting community transmission when infectious diseases such as influenza, measles, hepatitis A, B, and C, and the novel coronavirus are involved. However, infectious-disease treatment can become less effective due to antimicrobial resistance (AMR), a phenomenon that occurs when fungi, viruses, parasites and bacteria stop responding to medications over time. This can make infectious diseases incredibly harder to treat with conventional treatment protocols because antimicrobial and antibiotic medicines become less effective, increasing the risk of severe illness and death. In the case of infectious diseases, antimicrobial resistance can make…

MondayOct 23, 2023 9:45 am

Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Provides Insights on Definitive Agreement to Combine with GEDi Cube to Transform Medicine

Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to elevate therapeutic efficacy and patient care By joining forces, the two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development Renovaro’s intimate knowledge about vital aspects of the immune system and how cancers could respond to treatment may…

MondayOct 23, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Promising Results in Its Pursuit of Safe, Effective Treatments for Large, Underserved Population of Plaque Psoriasis Patients

Scinai announced positive results suggesting the therapeutic potential of its anti-IL-17 VHH antibodies (NanoAbs) in treating plaque psoriasis The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis The study also revealed that the outer skin layers regained their normal appearance The company aims to provide safe, efficacious, specific, and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients Scinai is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced…

FridayOct 20, 2023 3:20 pm

Scientists Find Potential to Reverse Prostate Cancer Treatment Resistance

Researchers say they may have found a new and more efficient means of treating prostate cancer that reverses the cancer’s resistance to treatment. Although treatment is fairly effective, prostate cancer can become resistant to treatment in some advanced cases and continue to grow despite low and even below-castrate level testosterone levels. Prostate cancer is the second most prevalent cancer type in American men after skin cancer, affecting around 288,300 men in the country and more than a million men globally every year. It has relatively favorable treatment outcomes, especially when the condition is diagnosed early. Many men have lived with…

ThursdayOct 19, 2023 1:06 pm

eCommerce Reshaping Consumer Healthcare Field, Report Says

E-commerce was born with the advent of the internet more than two decades ago, and it revolutionized business on a global scale. The internet opened an entirely new avenue for trade and granted companies access to a massively expanded market, allowing e-commerce to reach almost 19% of all global retail sales in 2022. Although digital health has been around for quite a while now, major e-commerce players such as Amazon and Walmart began making major investments in the healthcare sector in the wake of the coronavirus pandemic. The pandemic revealed that people are willing to seek medical help online if…

ThursdayOct 19, 2023 10:30 am

SOHM, Inc. (SHMN) Completes Acquisition of ABBIE Gene-editing Tech, Begins Preparations to Commercialize Solutions for Heart Disease

Generic drug manufacturer and distributor SOHM has completed the LOI process to acquire stem cell gene-editing technology ABBIE from CGA Intellectual Holdings Inc. The company expects the technology to provide it with commercialization revenues as it builds a solution for gene-enhanced stem cells that can be used to treat a number of diseased organs, beginning with heart ailments The edited-gene cells are expected to be used for in-human clinical trials by 2025, using a non-viral vector for inserting the genes into patients’ bodies SOHM believes the technology will provide it with a competitive advantage in a market expected to grow…

WednesdayOct 18, 2023 1:42 pm

Sonobiopsy Promises Easier Way to Diagnose Brain Tumors

Current brain tumor diagnosis protocols usually involve magnetic resonance imaging (MRI) and computerized tomography (CT) scans followed by tissue biopsy or surgical resection. Although tissue biopsies are less invasive than surgical resection, both are relatively invasive procedures that involve invading the skull to access brain tumors in various ways. Patients who would like a less invasive procedure also have the option of blood-based liquid biopsies. This inexpensive technique involves running biomarkers through the blood to obtain genetic and molecular tumor information to help inform treatment decisions. However, blood-based liquid biopsies aren’t as effective at diagnosing brain tumors as biomarkers from…